The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
The hospital has recently launched Radionuclide therapy
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
The company will manufacture a cancer immunotherapy product from 2022
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Subscribe To Our Newsletter & Stay Updated
